In the past decade, radiomics, radiogenomics, and nanoparticle-based molecular imaging have become an important focus area of ...

The management of hormone receptor–positive (HR+) early breast cancer has long relied on adjuvant endocrine therapy, which is ...

Following the successful debut of its Hair Growth Gummies, Xtressé (TM) expands its dermatologist- and-scientist-formulated offerings with the launch of the Xtressé (TM) Stress-Adaptive Hair Therapy ...

Not only do many people make therapy a years-long process, but they may not be getting its full benefits. Here's how to be a good consumer.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

We developed and externally validated a novel population-based model for predicting cancer-specific mortality free survival (CSM-FS) in trimodal therapy (TMT)-treated muscle-invasive bladder cancer ...

Patients at our institution with lung cancer and any RT Current Procedural Terminology (CPT) code from October 2015 to January 2024 were analyzed. RT claims were organized by treatment episode, and RT ...

Abstract: The paradigm of cancer therapy is rapidly shifting towards personalized precision medicine, yet current diagnostic approaches remain constrained by centralized laboratory infrastructure, ...